Sperm‑associated antigen 5 is a potential biomarker for poor prognosis in breast cancer

Zhou,Xiaoli; Jia,Lizhou; Sun,Yangyang; Xu,Lingyun; Wang,Xudong; Tang,Qi

doi:10.3892/ol.2018.9729

Sperm‑associated antigen 5 is a potential biomarker for poor prognosis in breast cancer

Authors:
- Xiaoli Zhou
- Lizhou Jia
- Yangyang Sun
- Lingyun Xu
- Xudong Wang
- Qi Tang
View Affiliations

Affiliations: Department of Pathology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China, Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China, Department of Clinical Bio‑bank, Nantong University Affiliated Hospital, Nantong, Jiangsu 226001, P.R. China
Published online on: November 19, 2018 https://doi.org/10.3892/ol.2018.9729
Pages: 1146-1152
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sperm‑associated antigen 5 (SPAG5) is currently considered to serve a role in promoting tumor cell growth and is overexpressed in several types of human cancer. However, to the best of our knowledge, the association of SPAG5 with molecular subtypes of patients with breast cancer (BC) remains to be fully investigated. Reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry on tissue microarrays were used in the current study to detect the expression levels of SPAG5 mRNA and protein, respectively, in BC. The association between SPAG5 mRNA and protein levels, and clinical characteristics and prognostic information were investigated. SPAG5 mRNA and protein levels were identified to be higher in BC tissues compared with matched adjacent nontumor tissues. High expression level of SPAG5 protein was associated with tumor size, histological grade, estrogen receptor expression, Ki‑67 expression, lymph node status, tumor‑node‑metastasis (TNM) stage and the triple‑negative BC subtype. In addition, high expression level of SPAG5 protein was associated with a poor prognosis in patients with BC. In summary, the current study suggests that SPAG5 is a novel and useful prognostic biomarker in BC.

View Figures

View References

1	Beiki O, Hall P, Ekbom A and Moradi T: Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: A population-based cohort study. Breast Cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
2	Yang YL, Qian XL and Fu L: Comparison of HER2 status of breast cancer between Chinese women in China and Chinese-American women in the US. Breast J. 23:764–765. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wang J, Li Q, Xu B, Zhang T, Chen S and Luo Y: Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chin J Cancer Res. 29:411–418. 2017. View Article : Google Scholar : PubMed/NCBI
4	Peng R, Luo C, Guo Q, Cao J, Yang Q, Dong K, Wang S, Wang K and Song C: Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene. 642:241–248. 2018. View Article : Google Scholar : PubMed/NCBI
5	Abrahams HJ, Gielissen MF, Schmits IC, Verhagen CA, Rovers MM and Knoop H: Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: A meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 27:965–974. 2016. View Article : Google Scholar : PubMed/NCBI
6	Rossing M, Østrup O, Majewski WW, Kinalis S, Jensen MB, Knoop A, Kroman N, Talman ML, Hansen TVO, Ejlertsen B and Nielsen FC: Molecular subtyping of breast cancer improves identification of both high and low risk patients. Acta Oncol. 57:58–66. 2018. View Article : Google Scholar : PubMed/NCBI
7	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
8	Stathopoulos GP, Malamos NA, Markopoulos C, Polychronis A, Armakolas A, Rigatos S, Yannopoulou A, Kaparelou M and Antoniou P: The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs. 25:950–957. 2014. View Article : Google Scholar : PubMed/NCBI
9	Xue J, Tarnasky HA, Rancourt DE and van Der Hoorn FA: Targeted disruption of the testicular SPAG5/deepest protein does not affect spermatogenesis or fertility. Mol Cell Biol. 22:1993–1997. 2002. View Article : Google Scholar : PubMed/NCBI
10	Shao X, Xue J and van der Hoorn FA: Testicular protein Spag5 has similarity to mitotic spindle protein Deepest and binds outer dense fiber protein Odf1. Mol Reprod Dev. 59:410–416. 2001. View Article : Google Scholar : PubMed/NCBI
11	Fitzgerald CJ, Oko RJ and van der Hoorn FA: Rat Spag5 associates in somatic cells with endoplasmic reticulum and microtubules but in spermatozoa with outer dense fibers. Mol Reprod Dev. 73:92–100. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhong W, Zhou Y, Li J, Mysore R, Luo W, Li S, Chang MS, Olkkonen VM and Yan D: OSBP-related protein 8 (ORP8) interacts with Homo sapiens sperm associated antigen 5 (SPAG5) and mediates oxysterol interference of HepG2 cell cycle. Exp Cell Res. 322:227–235. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kersten FF, van Wijk E, Hetterschijt L, Bauβ K, Peters TA, Aslanyan MG, van der Zwaag B, Wolfrum U, Keunen JE, Roepman R and Kremer H: The mitotic spindle protein SPAG5/Astrin connects to the Usher protein network postmitotically. Cilia. 1:22012. View Article : Google Scholar : PubMed/NCBI
14	Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH and Zheng M: SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 6:e17842015. View Article : Google Scholar : PubMed/NCBI
15	Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, et al: SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: A retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 17:1004–1018. 2016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Stovgaard ES, Nielsen D, Hogdall E and Balslev E: Triple negative breast cancer-prognostic role of immune-related factors: A systematic review. Acta Oncol. 57:74–82. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kierszenbaum AL: Spermatid manchette: Plugging proteins to zero into the sperm tail. Mol Reprod Dev. 59:347–349. 2001. View Article : Google Scholar : PubMed/NCBI
19	Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, et al: Triple-negative breast cancer: Present challenges and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zhang H, Li S, Yang X, Qiao B, Zhang Z and Xu Y: miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
21	Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, et al: Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS One. 9:e818432014. View Article : Google Scholar : PubMed/NCBI